Home

MBX Biosciences, Inc. - Common Stock (MBX)

34.80
+4.38 (14.40%)
NASDAQ · Last Trade: Dec 22nd, 4:45 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close30.42
Open30.93
Bid30.42
Ask35.50
Day's Range30.52 - 35.55
52 Week Range4.807 - 34.83
Volume985,138
Market Cap-
PE Ratio (TTM)4.531
EPS (TTM)7.7
Dividend & YieldN/A (N/A)
1 Month Average Volume948,648

Chart

About MBX Biosciences, Inc. - Common Stock (MBX)

MBX Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company leverages advanced science and technology to create novel drug candidates that aim to address unmet medical needs in these therapeutic areas. Through rigorous research and clinical trials, MBX aims to bring accessible and effective treatment options to patients suffering from conditions such as obesity, diabetes, and other hormone-related diseases, positioning itself as a key player in the biotechnology landscape. Read More

News & Press Releases

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry
Via MarketMinute · December 22, 2025
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestonesfool.com
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via The Motley Fool · December 3, 2025
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestonesfool.com
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via The Motley Fool · November 27, 2025
MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Studystocktwits.com
Via Stocktwits · September 22, 2025
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,
Via MarketMinute · November 7, 2025
This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
Via Benzinga · November 4, 2025
Which stocks have an unusual volume on Thursday?chartmill.com
Let's have a look at the stocks with an unusual volume in today's session.
Via Chartmill · September 25, 2025
Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga.com
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.
Via Benzinga · September 25, 2025
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarketbenzinga.com
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
Via Benzinga · September 25, 2025
Unusual volume stocks are being observed in Tuesday's session.chartmill.com
On Tuesday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · September 23, 2025
Stock Market Today: Nasdaq Futures Rise, S&P 500 Slips Amid Mixed Trade—Kenvue, Micron Tech, Nvidia In Focusbenzinga.com
U.S. stock futures were fluctuating on Tuesday following Monday's record advances. Futures of major benchmark indices were mixed.
Via Benzinga · September 23, 2025
AutoZone, Micron Technology And 3 Stocks To Watch Heading Into Tuesdaybenzinga.com
U.S. stock futures down, focus on AutoZone, Firefly Aerospace earnings, AAR Corp. results, MBX Biosciences public offering.
Via Benzinga · September 23, 2025
Top stock movements in today's session.chartmill.com
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · September 22, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · September 22, 2025
Top movers analysis in the middle of the day on 2025-09-22: top gainers and losers in today's session.chartmill.com
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · September 22, 2025
Gold Gains Over 1%; Quantum Computing Shares Plungebenzinga.com
Via Benzinga · September 22, 2025
Let's uncover which stocks are experiencing notable gaps during today's session.chartmill.com
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · September 22, 2025
PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · September 22, 2025
Dow Falls Over 100 Points; Chicago Fed National Activity Index Rises In Augustbenzinga.com
Via Benzinga · September 22, 2025
MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promiseinvestors.com
The company is working on an experimental treatment for a thyroid disease.
Via Investor's Business Daily · September 22, 2025
Monday's pre-market session: top gainers and loserschartmill.com
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · September 22, 2025
MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Studybenzinga.com
MBX Biosciences reported Phase 2 trial success for once-weekly canvuparatide, with strong efficacy, safety profile, and plans for Phase 3 in 2026.
Via Benzinga · September 22, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · September 22, 2025
Why MBX Biosciences Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · September 22, 2025
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · September 19, 2025